公开(公告)号：US12103958B2

公开(公告)日：2024-10-01

申请号：US17035327

申请日：2020-09-28

Applicant: PFIZER INC. ,  THE REGENTS OF THE UNIVERSITY OF CALIFORNIA

Inventor： Natasha Kay Crellin ,  Lauren Kate Ely ,  Jason Robles Reyes ,  Chia Chi Ho ,  Jeffrey A. Bluestone ,  Eleonora Trotta ,  Qizhi Tang

IPC: C07K14/705 ,  A61K39/00 ,  C12N15/63 ,  G01N33/50 ,  G01N33/68

CPC classification number: C07K14/70528 ,  A61K39/001129 ,  C12N15/63 ,  G01N33/505 ,  G01N33/68 ,  C07K2319/30 ,  G01N2333/70507

Abstract: The invention provides LFA3 polypeptide molecules, e.g., variant LFA3 fusion polypeptide molecules. The invention includes uses, and associated methods of using the LFA3 polypeptide molecules.

公开(公告)号：US20150110761A1

公开(公告)日：2015-04-23

申请号：US14382537

申请日：2013-03-01

Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA

Inventor： Qizhi Tang ,  Jeffrey A. Bluestone

IPC: A61K35/17 ,  C12N5/0783

CPC classification number: A61K35/17 ,  A61K31/436 ,  A61K31/5377 ,  A61K31/573 ,  A61K39/001 ,  A61K2300/00 ,  C12N5/0635 ,  C12N5/0637 ,  C12N2501/04 ,  C12N2501/2304 ,  C12N2501/515 ,  C12N2502/1107 ,  C12N2502/30

Abstract: The present disclosure relates generally to the manufacture of regulatory T cells (Tregs) for use in immunotherapy. In particular, the present disclosure relates to robust approaches for the expansion of alloantigen-reactive Tregs ex vivo. Alloantigen-reactive Tregs produced in this way are suitable for the induction and/or maintenance of immunologic tolerance in recipients of allogeneic transplants.

Abstract translation: 本公开一般涉及用于免疫治疗的调节性T细胞（Treg）的制造。 特别地，本公开涉及离体扩增同种抗原反应性Treg的有效方法。 以这种方式产生的异源抗原反应性Treg适用于诱导和/或维持同种异体移植受体的免疫耐受性。

公开(公告)号：US09801911B2

公开(公告)日：2017-10-31

申请号：US14382537

申请日：2013-03-01

Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA

Inventor： Qizhi Tang ,  Jeffrey A. Bluestone

IPC: C12N5/071 ,  C12N5/00 ,  C12N5/02 ,  A61K35/17 ,  A61K31/436 ,  A61K31/5377 ,  A61K31/573 ,  C12N5/0783 ,  A61K39/00 ,  C12N5/0781

CPC classification number: A61K35/17 ,  A61K31/436 ,  A61K31/5377 ,  A61K31/573 ,  A61K39/001 ,  A61K2300/00 ,  C12N5/0635 ,  C12N5/0637 ,  C12N2501/04 ,  C12N2501/2304 ,  C12N2501/515 ,  C12N2502/1107 ,  C12N2502/30

Abstract: The present disclosure relates generally to the manufacture of regulatory T cells (Tregs) for use in immunotherapy. In particular, the present disclosure relates to robust approaches for the expansion of alloantigen-reactive Tregs ex vivo. Alloantigen-reactive Tregs produced in this way are suitable for the induction and/or maintenance of immunologic tolerance in recipients of allogeneic transplants.

公开(公告)号：US11951136B2

公开(公告)日：2024-04-09

申请号：US16772078

申请日：2018-12-12

Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA ,  U.S. GOVERNMENT REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS

Inventor： Casey Ward ,  Qizhi Tang ,  Peter Stock ,  Gaetano Faleo ,  Gopika Nair ,  Matthias Hebrok ,  Wenhan Chang ,  Thuy Vo ,  Jeffrey A. Bluestone ,  Eleonora De Klerk

IPC: A61P3/10 ,  A61K9/00 ,  A61K35/39 ,  A61K35/55 ,  C12N5/071

CPC classification number: A61K35/55 ,  A61K9/0019 ,  A61K9/0024 ,  A61K35/39 ,  A61P3/10 ,  C12N5/0617 ,  C12N5/0676 ,  A61K2300/00 ,  C12N2506/02 ,  C12N2506/078

Abstract: Provided herein, inter alia, are methods and compositions for treating diabetes mellitus comprising co-transplantation of an insulin-producing cell and a cell derived from a parathyroid gland (PTG), a CD34+ cell derived from a parathyroid gland, a CD34+ cell derived from a stem cell, or other progenitor cell-derived CD34+ cell.

公开(公告)号：US20210017248A1

公开(公告)日：2021-01-21

申请号：US16981168

申请日：2019-03-15

Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA

Inventor： Jeffrey A. Bluestone ,  Qizhi Tang ,  Leonardo M.R. Ferreira

IPC: C07K14/725 ,  C07K14/705 ,  C07K16/28 ,  C12N5/0783 ,  A61K35/17 ,  A61P37/06

Abstract: Chimeric antigen receptor (CAR)-expressing T regulatory cells (Tregs) include intracellular co-stimulatory or inhibitory domains based on the biology, functions and activities of Tregs. The co-stimulatory or inhibitory domains modulate the Treg response, thereby, activating or suppressing an effector T cell (Teff) immune response to specific antigens.